Common use of Therapeutic Antibody Products Clause in Contracts

Therapeutic Antibody Products. 6.1.1 With respect to Therapeutic Antibody Products, Dyax shall pay to CAT the following payments upon achievement of the specified milestones by Dyax or a Dyax Sublicensee (or its sublicensee) for the first Therapeutic Antibody Product to achieve the relevant milestone: Initiation of first Phase I Clinical Trial US $ Initiation of first Phase III Clinical Trial US $ First filing for Marketing Authorisation in one Major Market country US $ Marketing Authorisation granted in the United States US $

Therapeutic Antibody Products. 6.1.1 With respect to Therapeutic Antibody Products, Dyax shall pay to CAT the following payments upon achievement of the specified milestones by Dyax or a Dyax Sublicensee (or its sublicensee) for the first Therapeutic Antibody Product to achieve the relevant milestone: Initiation of first Phase I Clinical Trial US $ $______________ Initiation of first Phase III Clinical Trial US $ $______________ First filing for Marketing Authorisation in one Major Market country US $ $______________ Marketing Authorisation granted in the United States US $______________

Therapeutic Antibody Products. 6.1.1 With respect to Therapeutic Antibody Products, Dyax shall pay to CAT the following payments upon achievement of the specified milestones by Dyax or a Dyax Sublicensee (or its sublicensee) for the first Therapeutic Antibody Product to achieve the relevant milestone: Initiation of first Phase I Clinical Trial US $ $[*****] Initiation of first Phase III Clinical Trial US $ $[*****] First filing for Marketing Authorisation in one Major Market country US $ $[*****] Marketing Authorisation granted in the United States US $[*****]

Therapeutic Antibody Products. 6.1.1 With respect to Therapeutic Antibody Products, Dyax shall pay to CAT the following payments upon achievement of the specified milestones by Dyax or a Dyax Sublicensee (or its sublicensee) for the first Therapeutic Antibody Product to achieve the relevant milestone: Initiation of first Phase I Clinical Trial US $ $[******] Initiation of first Phase III Clinical Trial US $ $[******] First filing for Marketing Authorisation in one Major Market country US $ $[******] Marketing Authorisation granted in the United States US $[******]